A Study of the Long-Term Safety of ABT-089 for Subjects With Mild-to-Moderate Alzheimer's Disease Who Participated in the M06-876 Study.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Pozanicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 01 Sep 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 01 Sep 2011 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual patient number (58) added as reported by ClinicalTrials.gov.